Search Results

Lyndra Therapeutics today announced the closing of a $101 million Series E financing round.

The late-stage pharmacokinetic study was stopped early due to efficacy at interim analysis, Lyndra Therapeutics said Thursday. A six-month safety study will start in the second half of 2024.

Lyndra Therapeutics today announced long-time Lyndra executive President and Chief Operations Officer Jessica Ballinger has been appointed President and CEO.

Lyndra Therapeutics today announced positive data from the STARLYNG-1 (LYN-005-C-301) study, comparing the pharmacokinetic (PK) profile of oral weekly risperidone (LYN-005) with immediate-release Risperdal administered daily to adults living with schizophrenia and schizoaffective disorder.

Lyndra Therapeutics announced the appointment of Kyle B. Haraldsen as Lyndra’s Chief Technology Officer and Helene Madonick, J.D., former Deputy General Counsel and Interim Director, Gender Equality Program Strategy at the Bill & Melinda Gates Foundation, and Ashish Singh, MBA, Senior Partner and former Healthcare Global Practice Leader at Bain & Company, to Lyndra’s Board of Directors.

Lyndra Therapeutics, a clinical-stage biopharmaceutical company working to make daily pills a thing of the past, today announced it has dosed the first participant in its pivotal clinical trial investigating oral weekly risperidone (LYN-005).

Lyndra Therapeutics, a clinical-stage biopharmaceutical company working to make daily pills a thing of the past, today announced it will present a poster on the results of a simulation-based predictive modeling study comparing the Positive and Negative Syndrome Scale (PANSS) scores produced by oral weekly risperidone (LYN-005) and oral daily risperidone at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting.

Lyndra Therapeutics today announced that its LYNX™ drug delivery platform was named the winner of the Fierce Life Sciences Innovation Awards 2022 award in the Drug Delivery Technology category.